Investors Face Losses as Securities Fraud Lawsuit Hits ADMA Biologics

The lawsuit alleges that ADMA Biologics failed to disclose critical information regarding its internal controls and business practices, specifically accusing the firm of using "channel stuffing" to create a misleading appearance of financial growth. These claims suggest that the company’s public statements lacked a reasonable basis, ultimately obscuring the true state of its operations from stakeholders.

Market confidence began to erode on March 24, 2026, when a report from Culper Research detailed allegations of undisclosed related-party distributors and improper rebates. This disclosure, followed by a subsequent rating downgrade from Cantor Fitzgerald, triggered a sharp decline in stock price. Over a two-day period in late March, the company's valuation dropped by more than 31%, followed by an additional 13.9% decline after the firm acknowledged it was reviewing the assertions. Reed Kathrein, a partner at Hagens Berman, stated that the firm is actively investigating the extent to which these misleading statements concealed the reality of ADMA's distribution channels.